# A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

> **NCT07008118** · PHASE1 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 120 (estimated)

## Conditions studied

- Myeloproliferative Neoplasms

## Interventions

- **DRUG:** INCA035784

## Key facts

- **NCT ID:** NCT07008118
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2028-03-14
- **Final completion:** 2029-12-14
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07008118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07008118, "A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07008118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*